Treatment Preferences Among Patients with Renal Cell Carcinoma: Results from a Discrete Choice Experiment
In this study, patients highlighted that improving survival time was the most important and that QoL is also an important consideration. Discussions during treatment decision-making may benefit from broader conversations around treatment characteristics, including impacts on QoL and convenience of the regimen.
Authors
- Oliver Will (ORCID: https://orcid.org/0000-0002-6514-8298)
- Sarah Guttenplan
- Xin Yin (ORCID: https://orcid.org/0000-0002-4441-4585)
- Kathleen Marie Beusterien (ORCID: https://orcid.org/0000-0001-7786-5422)
- Viviana Del Tejo
- Flavia Ejzykowicz
- Moshe Chaim Ornstein (ORCID: https://orcid.org/0000-0003-0184-3467)
- Marc DeCongelio (ORCID: https://orcid.org/0009-0004-5486-5584)
- Lisa Rosenblatt
- deMauri Mackie (ORCID: https://orcid.org/0000-0002-4941-1682)
- Grace Skiles (ORCID: https://orcid.org/0000-0003-0921-7356)
Institutions
- Cleveland Clinic (US)
- Oracle (United States) (US)
- Bristol-Myers Squibb (United States) (US)
- Bristol-Myers Squibb (Sweden) (SE)
Publication Details
- Journal
- Patient Preference and Adherence
- Published
- 2024-08-01
- DOI
- https://doi.org/10.2147/ppa.s460994
- Citations
- 5
- Primary Topic
- Organ Donation and Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 2.71
Funders
- Bristol-Myers Squibb
- American Society of Clinical Oncology